Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?

  title={Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?},
  author={Nagi B. Kumar and Kirsten Allen and Alan B. Cantor and Charles E. Cox and Harvey M. Greenberg and S. Shah and Gary H. Lyman},
  journal={Breast Cancer Research and Treatment},
There is a perception that tamoxifen causes weightgain in breast cancer patients. The purpose ofthis research study was to determine if weightgain is associated with tamoxifen therapy and toobserve the impact of weight gain on recurrenceand survival. Prognostic indicators, changes in weight, anddisease status from diagnosis to the end oftreatment were studied in 200 consecutive Stage Iand II breast cancer patients, not receiving systemicchemotherapy, admitted from 1986 to the present… 

Weight gain during adjuvant and neoadjuvant chemotherapy for breast cancer: an audit of 100 women receiving FEC or CMF chemotherapy.

A high incidence of weight gain was found in women treated with CMF or FEC chemotherapy and the literature on weight gain in breast cancer and possible interventions to avoid weight gain are discussed.

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

Wide-ranging and inconsistent results point to the need for further research to clarify annual weight change (loss, gain, stability) from BC diagnosis through 5 years of ET and beyond.

Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer

All three trials demonstrate that weight gain occurs primarily within the first 12 months of active treatment in a subset of patients, and in the prevention trials, weight gain does not differ between anastrozole, tamoxifen and placebo.

Longitudinal Patterns of Weight Gain after Breast Cancer Diagnosis: Observations beyond the First Year

Investigation of factors associated with weight gain over time in patients with invasive breast cancer during a period of predominantly anthracycline‐based adjuvant chemotherapy found that anthrACYcline therapy, age, and BMI were important.

Tamoxifen Use , and Outcomes in Women With Estrogen Receptor – Positive Early-Stage Breast Cancer

Because obesity was associated with increased risks of contralateral breast cancer, of other primary cancers, and of overall mortality, it may influence long-term outcomes for breast cancer survivors, and tamoxifen reduced breast cancer recurrence and mortality, regardless of BMI.

Does Switching from Tamoxifen to an Aromatase Inhibitor Result in Weight Change in Postmenopausal Breast Cancer Patients?~!2010-04-23~!2010-07-08~!2010-07-26~!

While patients switching from tamoxifen to an AI experienced modest weight gain in the 12 months prior to the switch, they did not experience further significant weight change after 12 months on an AI.

Weight, weight gain, and survival after breast cancer diagnosis.

Weight and weight gain were related to higher rates of breast cancer recurrence and mortality, but associations were most apparent in never-smoking women and in premenopausal than in postmenopausal women.

Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

Because obesity was associated with increased risks of contralateral breast cancer, of other primary cancers, and of overall mortality, it may influence long-term outcomes for breast cancer survivors and tamoxifen reduced breast cancer recurrence and mortality, regardless of BMI.

Weight gain in breast cancer survivors: prevalence, pattern and health consequences

A comprehensive review of the English language literature was conducted to investigate the frequency, magnitude and pattern of weight gain among breast cancer survivors, to identify factors that are associated with these changes and to review the clinical significance of weight Gain on disease free survival and overall health.



Weight gain in women with localized breast cancer — a descriptive study

It was concluded that the observed weight gain was not due to the use of adjuvant CMF and did not affect prognosis and further investigation was recommended to replicate the findings.

Why women gain weight with adjuvant chemotherapy for breast cancer.

A literature review was conducted to address the prevalence and magnitude of weight gain in women receiving adjuvant chemotherapy for early-stage breast cancer, and factors that might affect the amount of weight gained and mechanisms potentially responsible for weight gain.

Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.

It is concluded that, relative to observation, adjuvant chemotherapy is associated with greater weight gain in node-positive, postmenopausal breast cancer patients, and in premenopausal women, excessive weight gain may be associated with an increase in relapse and cancer-related deaths in the selected patients who show no evidence of recurrence during 60 weeks of adjUvant chemotherapy.

Weight gain with breast cancer adjuvant treatment

The coping style of logical analysis emerged as a significant predictor of disease recurrence, accounting for 28% of the variance in weight gain at 2 years, and development of interventions to control weight gain are discussed.

Body weight and prognosis in breast cancer.

In premenopausal women aged 45 years or more, the only group to benefit from adjuvant ovarian ablation, there was an interaction of treatment and weight, suggesting that weight exerts its influence on prognosis by a hormonal mechanism.

Weight gain after primary surgery for breast cancer - effect of tamoxifen

Premenopausal women receiving tamoxifen had greater weight gain than postmenopausal women on tamoxIFen therapy, and both groups saw weight gain seen in both groups, but was greater in the group receiving tamxifen.

Tamoxifen: how boldly to go where no women have gone before.

  • R. Gray
  • Medicine
    Journal of the National Cancer Institute
  • 1993
Tamoxifen has such a substantial effect on mortality because breast cancer is a common disease, and moderate improvements in the treatment of common diseases save more lives than the larger improvements seen in less common diseases such as fJtadgkin's disease or childhood leukemia.

The association of body weight with recurrent cancer of the breast

Diet and weight reduction may represent empirical means for improving the prognosis of heavy individuals with early stages of breast cancer.

Weight gain in patients with breast cancer receiving adjuvant treatment as a function of restraint, disinhibition, and hunger.

The restraint-disinhibition model is used to understand susceptibility to weight gain, and the potential impact of exercise and dysphoria to suggest that weight gain can be controlled by diet and exercise based on measurable dietary patterns.

Breast cancer chemoprevention tamoxifen: Current issues and future prospective

Key issues include the potential for interaction between tamoxifen and dietary fat reduction, the cost and cost‐effectiveness of wide scale (or selective) implementation of positive results, and the generalizability of study results to socioeconomically disadvantaged and racial and ethnic minority populations that historically have been under‐represented in medical clinical trials.